Biomarin Pharmaceutical (BMRN) Cash from Financing Activities (2009 - 2026)

Biomarin Pharmaceutical has disclosed Cash from Financing Activities across 18 years of filings, most recently posting $813.2 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 2196.93% year-over-year to $813.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $809.6 million (up 254.96% YoY) and the FY2025 annual result came in at -$42.4 million, up 91.95% from the prior year.
• Cash from Financing Activities improved to $813.2 million in Q1 2026, from $3.2 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $813.2 million in Q1 2026 and troughed at -$499.1 million in Q3 2024.
• A 5-year average of $12.2 million and a median of -$788000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 63240.74% — and 2026, when it soared 2196.93%.
• Tracing BMRN's Cash from Financing Activities over 5 years: stood at $10.9 million in 2022, then declined by 0.27% to $10.8 million in 2023, then slumped by 73.63% to $2.9 million in 2024, then increased by 10.42% to $3.2 million in 2025, then surged by 25657.59% to $813.2 million in 2026.
• Business Quant data shows BMRN's Cash from Financing Activities at $813.2 million in Q1 2026, $3.2 million in Q4 2025, and -$2.2 million in Q3 2025.